Physician profile
Raya Galibov
NPI 1912008855
$27,694.74
in general payments reported to CMS, 2019-2025
62 companies · $4,033 in 2025
The $4,033 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,423 · 2022: $6,781 · 2023: $10K · 2024: $3,347 · 2025: $4,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,900 · Consulting Fee: $595 · Education: $82.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,913.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,900.00 |
| Consulting Fee | $595.00 |
| Education | $82.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $8,566.29 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $2,389.86 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $2,078.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,004.98 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Novo Nordisk INC | $1,110.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,043.14 | 2021-2025 | |
| Mannkind Corporation | $987.84 | 2021-2025 | Afrezza |
| Alexion Pharmaceuticals, INC. | $908.46 | 2021-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $740.11 | 2021-2025 | |
| Beta Bionics, INC. | $686.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $588.17 | 2021-2025 | Evenity, Prolia, Tepezza |
| Pfizer INC. | $392.85 | 2023-2025 | |
| Astellas Pharma US INC | $367.05 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.47 | 2021-2025 | Jardiance |
| Ascensia Diabetes Care US INC. | $338.78 | 2021-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $334.56 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $313.84 | 2021-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $272.65 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $264.41 | 2021 | |
| Exact Sciences Corporation | $242.44 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $234.85 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Kyowa Kirin, INC. | $205.30 | 2022-2025 | Crysvita |
| Verity Pharmaceuticals INC. | $195.82 | 2024-2025 | Tlando, Trelstar |
| Abbott Laboratories | $185.81 | 2021-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $177.36 | 2021-2025 | Unithroid |
| Radius Health, INC. | $153.97 | 2023-2025 | Tymlos, Binosto |
| Althera Pharmaceuticals LLC | $153.00 | 2022 | |
| Lifescan, INC. | $150.59 | 2021-2022 | |
| Ibsa Pharma INC. | $150.43 | 2021-2023 | Tirosint, Licart |
| Insulet Corporation | $147.27 | 2022-2025 | Omnipod |
| Acella Pharmaceuticals, LLC | $130.45 | 2023-2025 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Intra-Sana Laboratories | $113.09 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Biohaven Pharmaceutical Holding Company Ltd. | $108.81 | 2022 | |
| Medtronic, INC. | $107.28 | 2021-2024 | Minimed 780g |
| Corcept Therapeutics | $104.69 | 2022-2025 | Korlym |
| Cequr Corporation | $103.18 | 2022-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $101.73 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $90.80 | 2021 | |
| Acerus Pharmaceuticals Corporation | $67.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $60.80 | 2021 | |
| Amarin Pharma, INC. | $60.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.72 | 2024 | |
| Neurocrine Biosciences, INC. | $56.53 | 2025 | |
| Glaxosmithkline, LLC. | $56.50 | 2022-2023 | Shingrix, Boostrix |
| Vistapharm, INC. | $55.94 | 2021 | |
| Halozyme INC | $53.84 | 2023 | |
| Madrigal Pharmaceuticals | $52.22 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $47.99 | 2025 | Isturisa |
| Horizon Therapeutics Plc | $47.47 | 2022 | |
| Zealand Pharma US, INC. | $46.19 | 2021 | |
| Currax Pharmaceuticals LLC | $32.39 | 2022-2024 | Contrave |
| Eisai INC. | $31.90 | 2025 | |
| Tandem Diabetes Care, INC. | $24.13 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Clarus Therapeutics INC. | $21.97 | 2021 | |
| Lundbeck LLC | $21.89 | 2022 | |
| Vivus LLC | $21.43 | 2022 | |
| Chiesi USA, INC. | $20.72 | 2024 | Mycapssa |
| Avion Pharmaceuticals | $20.69 | 2024 | NP Thyroid 60 |
| Tolmar, INC. | $19.82 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raya Galibov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.